BioLib Technologies ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  9.2% 6.4% 4.6% 4.7% 1.6%  
Credit score (0-100)  28 37 44 45 73  
Credit rating  BB BBB BBB BBB A  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 8.2  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  173 1,453 1,901 2,150 4,021  
EBITDA  -157 -46.9 254 159 1,596  
EBIT  -157 -57.3 241 152 1,596  
Pre-tax profit (PTP)  -156.6 -58.5 236.4 148.6 1,595.6  
Net earnings  -126.2 -46.6 183.4 114.8 1,243.5  
Pre-tax profit without non-rec. items  -157 -58.5 236 149 1,596  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 20.7 7.1 0.0 0.0  
Shareholders equity total  174 127 311 425 1,669  
Interest-bearing liabilities  304 395 100 0.0 280  
Balance sheet total (assets)  523 773 552 877 3,212  

Net Debt  -171 76.9 -127 -314 -1,395  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  173 1,453 1,901 2,150 4,021  
Gross profit growth  0.0% 737.7% 30.9% 13.1% 87.0%  
Employees  1 6 6 5 3  
Employee growth %  0.0% 500.0% 0.0% -16.7% -40.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  523 773 552 877 3,212  
Balance sheet change%  0.0% 47.8% -28.6% 58.8% 266.1%  
Added value  -156.6 -46.9 254.1 165.5 1,596.1  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 10 -27 -14 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 1.0 2.0 3.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -90.3% -3.9% 12.6% 7.1% 39.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -29.9% -8.8% 36.3% 21.2% 78.3%  
ROI %  -32.8% -11.5% 51.5% 36.3% 134.8%  
ROE %  -72.6% -30.9% 83.7% 31.2% 118.7%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  33.2% 16.5% 56.2% 48.5% 52.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  109.0% -164.0% -50.0% -197.8% -87.4%  
Gearing %  174.9% 310.4% 32.2% 0.0% 16.8%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.4% 1.7% 6.5% 3.5%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.4 1.3 3.8 1.9 2.1  
Current Ratio  1.4 1.3 3.8 1.9 2.1  
Cash and cash equivalent  474.7 318.2 227.2 314.5 1,675.3  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  155.8 152.8 387.1 399.8 1,643.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  -157 -8 42 33 532  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -157 -8 42 32 532  
EBIT / employee  -157 -10 40 30 532  
Net earnings / employee  -126 -8 31 23 414